Zacks: Brokerages Anticipate Surface Oncology Inc (SURF) Will Post Earnings of -$0.66 Per Share
Analysts predict that Surface Oncology Inc (NASDAQ:SURF) will post earnings of ($0.66) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Surface Oncology’s earnings. The company is expected to announce its next earnings results on Tuesday, November 13th.
On average, analysts expect that Surface Oncology will report full year earnings of ($2.10) per share for the current fiscal year. For the next financial year, analysts anticipate that the firm will post earnings of ($2.73) per share. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Surface Oncology.
Surface Oncology (NASDAQ:SURF) last released its earnings results on Tuesday, August 14th. The company reported ($0.73) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.76) by $0.03. The firm had revenue of $2.43 million during the quarter.
Several large investors have recently bought and sold shares of SURF. Atlas Venture Associates IX LLC bought a new position in shares of Surface Oncology in the 2nd quarter worth $75,767,000. Victory Capital Management Inc. bought a new position in shares of Surface Oncology in the 2nd quarter worth $9,263,000. Dean Capital Investments Management LLC bought a new position in shares of Surface Oncology in the 2nd quarter worth $489,000. Bank of New York Mellon Corp bought a new position in shares of Surface Oncology in the 2nd quarter worth $248,000. Finally, Schwab Charles Investment Management Inc. bought a new position in shares of Surface Oncology in the 2nd quarter worth $518,000. Institutional investors and hedge funds own 63.32% of the company’s stock.
NASDAQ SURF opened at $10.56 on Tuesday. Surface Oncology has a 52 week low of $8.64 and a 52 week high of $18.18.
About Surface Oncology
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27.
Further Reading: Fiduciary
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.